Chiara Senti

Chiara Senti

Auto-generated profile, based on publicly available information

Chiara Senti

Division of Medical Oncology, ASST of Cremona, Hospital of Cremona, Cremona, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
Michele GhidiniMichele Ghidini
Michele Ghidini
JHJens Hahne
Jens Hahne
CSChiara Senti
Chiara Senti
THTimon Heide
Timon Heide
PPPaula Z Proszek
Paula Z Proszek
NVNicola Valeri
Nicola Valeri
Purpose: We tested whether circulating tumor DNA (ctDNA) changes may be used to assess early response and clinical outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line systemic anticancer therapy (SACT). Experimental Design: Eight hundred sixty-two plasma samples were collected 4-weekly from baseline (BL) until disease progression in patients with mCRC receiving first-line SACT. ctDNA was tested using tissue-agnostic next-generation sequencing panels. ctDNA normalization was defined as ≥99% clearance after 1 month of therapy (Mo1) in the three variants with the highest allele frequency in BL ctDNA. Results: Eighty-three paired samples from 75 patients were available for analysis. Twelve pairs (14.4%) showed no variants in either BL or Mo1. In the remaining 71 comparisons (65 patients), 37 (52.1%) showed ctDNA normalization at Mo1. Patients who cleared ctDNA had significantly longer overall (45.6 months) and progression-free survival (13.9 months) compared with nonnormalized patients [overall survival = 22.6 months (log-rank P = 0.01) and progression-free survival = 10.7 months (log-rank P = 0.036), respectively]. In addition, a higher response rate was observed in patients with ctDNA clearance (72.9%) compared with nonnormalized cases (38.2%). Longitudinal sequencing of at least four time points in patients with a progression-free survival of >10 months showed emerging variants in 47.8% of cases; in all these patients, the trajectory of these new “outlier” variants seemed in stark contrast with the clinical–radiological course of disease and the trend in other mutations. Conclusions: ctDNA clearance represents an early indicator of benefit from SACT in patients with mCRC; serial tracking of multiple variants is warranted to improve specificity and avoid misleading information due to the emergence of mutations of unknown clinical significance.

17 February 2025
Verified
Other
Open access
Michele GhidiniMichele Ghidini
Michele Ghidini
JHJens Hahne
Jens Hahne
CSChiara Senti
Chiara Senti
THTimon Heide
Timon Heide
PPPaula Z Proszek
Paula Z Proszek
NVNicola Valeri
Nicola Valeri
Supplementary Data 2 from Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line Chemotherapy


17 February 2025
Verified
Other
Open access
Michele GhidiniMichele Ghidini
Michele Ghidini
JHJens Hahne
Jens Hahne
CSChiara Senti
Chiara Senti
THTimon Heide
Timon Heide
PPPaula Z Proszek
Paula Z Proszek
NVNicola Valeri
Nicola Valeri
Supplementary Data 1,4 from Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line Chemotherapy


17 February 2025
Verified
Other
Open access
Michele GhidiniMichele Ghidini
Michele Ghidini
JHJens Hahne
Jens Hahne
CSChiara Senti
Chiara Senti
THTimon Heide
Timon Heide
PPPaula Z Proszek
Paula Z Proszek
NVNicola Valeri
Nicola Valeri
Supplementary Data 1,4 from Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line Chemotherapy